Skip to main content

KEWAUNEE SCIENTIFIC CORP /DE/

For the period ended Jan 31, 2026. Filed Mar 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jan 31, 2026 · Filed Mar 13, 2026

KEQU$34.12+0.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2026

or

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number 0-5286

KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware38-0715562
(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.)
2700 West Front StreetStatesville, North Carolina28677-2927
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (704)873-7202

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of Exchange on which registered

Common Stock, $2.50 par value KEQU NASDAQ Global Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No☒

As of March 10, 2026, the registrant had outstanding 2,866,384 shares of Common Stock.

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

For The Quarterly Period Ended January 31, 2026

Page Number
PART I. FINANCIAL INFORMATION
Item 1. · Condensed Consolidated Financial Statements
Condensed Consolidated Statements of Operations (unaudited)– Three and Nine Months Ended January 31, 2026 and 20251
Condensed Consolidated Statements of Comprehensive Earnings (unaudited)– Three and Nine Months Ended January 31, 2026 and 20252
Condensed Consolidated Statements of Stockholders' Equity (unaudited)– Three and Nine Months Ended January 31, 2026 and 20253
Condensed Consolidated Balance Sheets– January 31, 2026 (unaudited) and April 30, 20254
Condensed Consolidated Statements of Cash Flows (unaudited)– Nine Months Ended January 31, 2026 and 20255
Notes to Condensed Consolidated Financial Statements (unaudited)7
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations20
Item 3.Quantitative and Qualitative Disclosures About Market Risk22
Item 4.Controls and Procedures23
PART II. OTHER INFORMATION
Item 1A.Risk Factors24
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds24
Item 5.Other Information24
Item 6.Exhibits25
SIGNATURE26

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.